Indigo Diabetes nv announced that it has received €38,000,000 in its series B round of funding co-led by new investor, Fund+ NV and existing investors, Thuja Capital Healthcare Fund II, a fund managed by Thuja Capital Management B.V., Participatiemaatschappij Vlaanderen NV and Sensinnovat bvba on July 27, 2020. The transaction includes participation from new investors, Ackermans & Van Haaren NV (ENXTBR:ACKB), imec.xpand, a fund managed by IMEC, Investment Arm, Capricorn Digital Growth Fund, a fund managed by existing investor, Capricorn Partners, Qbic II, a fund managed by existing investor, QBIC Venture Partners, Titan-Baratto NV, and series A investors, including Fidimec NV, Manuardeo, Capricorn ICT Arkiv NV, a fund managed by Capricorn Partners, Qbic Arkiv Fund, a fund managed by QBIC Venture Partners and PowerGraph NV. The company has raised more than €45,000,000 in funding till date. As part of the round, Jan Van den Bossche of Fund+ NV has joined the company's board of directors.